Different Histologic Types and Pretreatment Factors Associated with Anemia in Non-small Cell Lung Cancer Patients

Main Article Content

Benyapatch Eiamthanasinchai

Abstract

Background: Anemia is common problem in lung cancer which impaired the effectiveness of treatment and quality of life. Lung cancer is divided into several types according to the histology. This study aimed to identified which histologic types of non-small cell lung cancer and factors associated with anemia in pretreatment lung cancer patients. The assessment may help in optimizing the care of anemic patients with lung cancer.
Objective: To determine the histologic types of lung cancer and factors associated with anemia in pretreatment non-small cell lung cancer patients.
Study design: Retrospective case-control study.
Methods: Non-small cell lung cancer patients in Surin hospital with histologically confirmed that were reviewed between January 1st, 2014 and June 30th, 2018 from electronic databases. Histologic types of lung cancer, clinical characteristics and laboratory tests were collected in all patients.
Results: One hundred and eighty four non-small cell lung cancer patients in Surin hospital were recruited and classified into 2 groups: anemia and non-anemia group equally. The histologic types of lung cancer were adenocarcinoma, squamous cell carcinoma, large cell carcinoma and others were significantly differences between anemia and non-anemia groups (p=0.011). Squamous cell carcinoma was association with anemia group more than other types(p=0.004) and adenocarcinoma was association with non-anemia group(p=0.003). Factors that significantly associated with anemia in non-small cell lung cancer were albumin <3.5 g/dl (OR=3.64, 95% CI: 0.14-0.45, p<0.001) and WBC <5000 cells/uL (OR=6.93, 95% CI: 0.01-0.67, p=0.047).
Conclusion: Histologic types of non-small cell lung cancer were significantly differences between anemia and non-anemia groups. Squamous cell carcinoma was massociated with anemia. The factors associated with anemia were albumin<3.5 g/dl and WBC <5000 cells/uL. These factors can be resolved for optimize the treatment, reduced complications from blood transfusion or used erythropoietin and improved quality of life.
Keywords: anemia, non-small cell lung cancer, pretreatment

Keywords

Article Details

Section
Original Articles

References

1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40(15):2293-306.

2. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32(4):605-44.

3. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91.

4. Hellmann MD, Chaft JE, Rusch V, Ginsberg MS, Finley DJ, Kris MG, et al. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer Chemother Pharmacol 2013;72(2):453-61.

5. Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68 Suppl 1:3-11.

6. Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47(1):1-11.

7. Gauthier I, Ding K, Winton T, Shepherd FA, Livingston R, Johnson DH, et al. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. Lung Cancer 2007;55(3):357-63.

8. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Impact of preoperative hemoglobin level on survival of non-small cell lung cancer patients. Anticancer Res. 2008;28(3B):1947-50.

9. Zhang YH, Lu Y, Lu H, Zhang MW, Zhou YM, Li XL. Pretreatment Hemoglobin Level Is an Independent Prognostic Factor in Patients with Lung Adenocarcinoma. Can Respir J 2018;2018:6328127.

10. Kuzuya M, Izawa S, Enoki H, Okada K, Iguchi A. Is serum albumin a good marker for malnutrition in the physically impaired elderly? Clin Nutr 2007;26(1):84-90.

11. Doweiko JP, Nompleggi DJ. The role of albumin in human physiology and pathophysiology, Part III: Albumin and disease states. JPEN J Parenter Enteral Nutr 1991;15(4):476-83.

12. Doweiko JP, Nompleggi DJ. Role of albumin in human physiology and pathophysiology. JPEN J Parenter Enteral Nutr 1991;15(2):207-11.

13. Frangos E, Trombetti A, Graf CE, Lachat V, Samaras N, Vischer UM, et al. Malnutrition in Very Old Hospitalized Patients: A New Etiologic Factor of Anemia? J Nutr Health Aging 2016;20(7):705-13.

14. Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non hematological malignancies--a possible tumor-associated marker. J Cancer Res Clin Oncol 1986;111(1):54-8.

15. Chen M, Krishnamurthy A, Mohamed AR, Green R. Hematological disorders following gastric bypass surgery: emerging concepts of the interplay between nutritional deficiency and inflammation. Biomed Res Int 2013;2013:205467.

16. Brechot JM, Roche N, Marichy C, Lebeau B, Debieuvre D, Darneau G, et al. [Treatment of anemia and bone metastasis in metastatic non-small-cell lung cancer. A French survey]. [Article in French]. Rev Pneumol Clin 2005;61(1 Pt 1):23-9.

17. Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program 2008:159-65.